|
|
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor
RATIONALE: Vaccines made from gene-modified tumor cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells. Combining vaccine therapy with cyclophosphamide and interferon alfa may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of combining vaccine therapy with interferon alfa and cyclophosphamide in treating patients who have stage IV breast cancer.
100 项与 Wiseman Research Initiatives LLC 相关的临床结果
0 项与 Wiseman Research Initiatives LLC 相关的专利(医药)
100 项与 Wiseman Research Initiatives LLC 相关的药物交易
100 项与 Wiseman Research Initiatives LLC 相关的转化医学